Slide 1: Reigniting Tecan's Growth Story – Half year results
REIGNITING TECAN’S GROWTH STORY Half year results August 11, 2026
Slide 2: Agenda
Agenda 1. Introduction 2. Financial results H1 2026 3. Update on program Rewired & outlook 2 CO NF I DENT I AL
Slide 3: Financial results H1 2026 – highlights
Financial results H1 2026 – highlights Sales Order entry CHF 427.5 m CHF 444.3 m (+3.4% LC) (+3.0% LC) Adj. EBITDA EPS Adj. EPS Cash flow CHF 64.5 m CHF 0.99 CHF 2.62 CHF 17 m (15.1% of Sales) (-29.8%) (-1.5%) (-71.7%) Note: Reconciliations to adjusted EBITDA and EPS are provided on slide 20. 3 CO N
Slide 4: Anticipated market trends 2026
Anticipated market trends 2026 Trends developed as expected and it is too early to call a change in trend for the second half Academia Biopharma Diagnostics MedTech & government Ongoing uncertainty Increased CAPEX in Solid demand driven Solid growth in and limited funding targeted growth areas by ad
Slide 5: Financials H1 2026, a detailed look
FINANCIALS H1 2026, A DETAILED LOOK Camila Japur, CFO
Slide 6: H1 2026 sales and order entry performance
H1 2026 sales and order entry performance SALES 439.5 427.5 SALES H1 2026 VS. 2025 CHF m 413.6 › Reported sales -2.7% in CHF, +3.4% in LC (LC) › Q2 growth momentum sustained: +3.4% in LC 2025 2026 ORDER ENTRY H1 2026 ORDER ENTRY 458.3 › -3.1% in CHF and +3.0% in LC 444.3 › Book-to-bill ratio at 1.04
Slide 7: H1 2026 segment sales
H1 2026 segment sales LIFE SCIENCES BUSINESS › Reported sales -3.2% in CHF, +3.1% in LC › Biopharma & Diagnostics: continued strong performance SEGMENT SALES › Academia & Government: demand still impacted by funding uncertainty › Q2: sales +4.6% in LC Life Sciences Business Partnering Business › Boo
Slide 8: H1 2026 EBITDA
H1 2026 EBITDA EBITDA ADJUSTED EBITDA 54.9 65.7 64.6 › Adj. EBITDA reached CHF 64.6 m, CHF m 46.6 CHF 1.1 m below H1 2025 ADJUSTED EBITDA MARGIN EBITDA adj. EBITDA 2025 2026 › Adjusted EBITDA margin up to 15.1% (H1 2025: 15.0%) ADJ. EBITDA MARGIN (% OF SALES) MAIN EFFECTS EXPLAINING DIFFERENCE OF +1
Slide 9: H1 2026 EBITDA reconciliation and Rewired
H1 2026 EBITDA EBITDA RECONCILIATION REWIRED › Comprehensive transformation program Reported EBITDA (in CHF m) 46.6 › 2026: year of “Reset” with adjusted EBITDA margin outlook of 15.5%-16.5% › Rewired (incl. restructuring) +7.6 › 2028 target: 20% adjusted EBITDA margin › Total OPEX to deliver 'Rewir
Slide 10: H1 2026 segment profitability
H1 2026 segment profitability ADJ. EBITDA (IN CHF M) LIFE SCIENCES BUSINESS 46.9 46.3 › Adj. EBITDA margin amounted to 13.8% of sales CHF m 26.4 24.7 › Factors contributing include: › (-) Tariffs › (-) Exchange rates Life Sciences Business Partnering Business › (+) Sales volumes 2025 2026 › (+) Oper
Slide 11: H1 2026 net profit and earnings per share
H1 2026 net profit and earnings per share ADJ. NET PROFIT 33.7 NET PROFIT 32.5 › Adjusted net profit: CHF 32.5 m (H1 2025: CHF 33.7 m) CHF m › Reported net profit: CHF 12.3 m (H1 2025: CHF 17.9 m) › Factors contributing include: › (-) EBIT › (-) Financial result 2025 2026 › (+) Tax rate slightly low
Slide 12: H1 2026 cash flow
H1 2026 cash flow CASH FLOW FROM OPERATIONS OF CHF 17.0 M (H1 2025: CHF 60.0 M) › Higher accounts receivable from increased sales late in the period; +4.3 -73.2 +17.0 DSO at 47 days (H1 2025: 45 days) › Inventory increase to strengthen supply chain resilience › Higher payments, including tax payment
Slide 13: Program Rewired and Outlook
PROGRAM REWIRED AND OUTLOOK Monica Manotas, CEO
Slide 14: Future-proofing Tecan
Future-proofing Tecan Rewired program: Delivering CHF 1 bn revenue, 20% adj. EBITDA 1 2 Commercial 3 Operational 2028 TARGETS Portfolio discipline excellence excellence 1 bn › Build on our strengths › Sharper segmentation › Scalable, resilient operations that Sales CHF m › Invest in scalable, differ
Slide 15: Update on program Rewired
Update on program Rewired Rewired program: Delivering CHF 1 bn revenue, 20% adj. EBITDA 1 Portfolio › Closed Boston design site in April discipline › Advanced exit from selected Tecan Genomics activities 2 Commercial › Building ecosystem to position Tecan as automation partner of choice for AI-power
Slide 16: Financial outlook 2026 confirmed
Financial outlook 2026 confirmed Sales Adj. EBITDA margin +LSD (LC) 15.5-16.5% 16.5% 16.1% +40 to -60 bps 140 bps 15.5% -40 bps 15.1% 2025 fx impact Tariffs Underlying 2026 EBITDA adj. improvement EBITDA adj. 16 CO NF I DENT I AL
Slide 17: Confirming outlook and targets
Confirming outlook and targets Measure success through clear financial targets based on transparent roadmap 2026 2028 Beyond 2028 Sales Sales Sales +LSD 1 bn +MSD/HSD (LC) (LC) (LC) Adj. EBITDA margin Adj. EBITDA margin Adj. EBITDA margin 15.5-16.5% 20% >20% Any changes to tariff rates may impact th
Slide 18: Key points to take away
Key points to take away Focused on above market growth and value creation for shareholders › Substantial progress in H1, with above market growth, good momentum in Life Sciences; Partnering on track. › Significant opportunity to realize the full potential of Tecan, 'Rewired' progressing well, expect
Slide 19: @TECAN.
2 @TECAN.
Slide 20: Appendix: Reconciliation of adjusted consolidated statement of profit or loss
Appendix Reconciliation of adjusted consolidated statement of profit or loss 20 CO NF I DENT I AL
Slide 21: @TECAN.
@OTECAN.
Slide 22: www.tecan.com
Tecan – Who we are Tecan Group Ltd. makes every effort to include accurate and up-to-date information, however, it is possible that omissions or errors might have occurred. Tecan Group At Tecan we are driven to improve people’s lives and health. We do this by empowering our Ltd. cannot, therefore, m